The University of Texas System

Research Development Foundation

Aemase, Inc.

Aerase, Inc.

Harvard College

Other

Genentech, Inc.

Cornell University

Tel Aviv University

Therasense, Inc.

Gma Technologies LLC

George Georgiou

Everett Stone

Brent L Iverson

Wei-Cheng Lu

John Blazeck

Chang-Han Lee

Sang Taek Jung

Barrett R Harvey

Tae Hyun Kang

Paul Henry Bessette

Edward M Marcotte

Yariv Mazor

Jonathan R Beckwith

Joseph Taft

Jason Lavinder

William Kelton

Daniel Ritz

Matthew DeLisa

Amihay Freeman

Gang Chen

Christos Karamitros

Francois Baneyx

Nicholas Marshall

Daniel Boutz

Yariv Wine

Li Yi

Sai Reddy

Andrew Hayhurst

Jeffrey G Thomas

Fredrik Aslund

Jackie Eun-ah Lim

Adam Heller

James Robert Swartz

Andrew D Ellington

Joseph A Francisco

Jennifer A Maynard

Xin Ge

Joseph Desautelle

Shira Cramer

Erik L Johnson

Nishant Mehta

Scott Hunicke-Smith

Brandon Dekosky

Andy Ellington

Dujduan Waraho

Danny Boutz

Laura Segatori

Melinda Faulkner

Stephanie Gon

Ki Jun Jeong

Thierry De Lumley-Woodyear

Elizabeth A Burks

Ji Oiu

Marc Ostermeier

Charles F Earhart

Gerald E Speitel, Jr

Patricia Phelps

Gregory C Ippolito

Jonathan R Mcdaniel

William N Voss

Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.

Human Kynureninase enzymes and uses thereof

Methods and compositions relating to the engineering of an improved protein with homocyst(e)inase enzyme activity are described. For example, there are disclosed modified cystathionine-γ-lyase (CGL) enzymes comprising one or more amino acid substitutions and capable of degrading homocyst(e)ine. Furthermore, provided are compositions and methods for the treatment of homocystinuria or hyperhomocysteinemia with homocyst(e)ine depletion using the disclosed enzymes or nucleic acids.

Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria

In some aspects, mutant or variant Fc domains are provided that exhibit increased binding to FcRn and increased half-life after administration in vivo. The Fc domain may be comprised in a glycosylated or aglycosylated antibody. Methods for using the mutant or variant Fc domains or polypeptides comprising the mutant or variant Fc domains are also provided.

Engineered antibody Fc variants for enhanced serum half life

Methods are provided for identifying tumor-specific antibodies and/or T-cell receptors by paired mRNA sequencing from individual immune cells in sentinel lymph nodes and comparison of these sequences with corresponding mass spectroscopy data from a subject having a cancer. Novel tumor-specific antibodies (e.g., NY-ESO-1-binding antibodies) are also provided.

Tumor specific antibodies and T-cell receptors and methods of identifying the same

Human kynureninase enzymes and uses thereof

Methods and composition related to the engineering of a novel protein with methionine-&#x3b3;-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-&#x3b3;-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.

Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof

Human kynureninase enzyme variants having improved pharmacological properties

Nucleic acids encoding kynurenine depleting enzymes

Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-&#x3b3;-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.

Engineered primate cystine/cysteine degrading enzymes as antineogenic agents

Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain are provided. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fc domain that selectively binds C1q, and optionally activating Fc receptors, but that is significantly reduced for binding to the inhibitory Fc&#x3b3;RIIb receptor. Furthermore, methods and compositions are provided for promoting complement dependent cytotoxicity (CDC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or a different non-Fc binding domain.

Engineered immunoglobulin Fc polypeptides displaying improved complement activation

Provided are methods for the identification of mutant kinases that are resistant to inhibition by a kinase inhibitor. In some embodiments, the methods may be used to assess a test compound or kinase inhibitor for the risk of the development of resistance in vivo, e.g., during clinical administration to treat a disease such as a cancer.

Methods for predicting kinase inhibitor resistance

Administration of kynurenine depleting enzymes for tumor therapy

Methods and compositions relating to the engineering of an improved protein with homocyst(e)inase enzyme activity are described. For example, there are disclosed modified cystathionine-&#x3b3;-lyase (CGL) enzymes comprising one or more amino acid substitutions and capable of degrading homocyst(e)ine. Furthermore, provided are compositions and methods for the treatment of homocystinuria or hyperhomocysteinemia with homocyst(e)ine depletion using the disclosed enzymes or nucleic acids.

Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine-&#x3b3;-lyases comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cancer and cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes.

Engineered primate cystine/cysteine degrading enzymes for therapeutic uses

Growing community of inventors

Austin, TX, United States of America

George Georgiou